Cannabinoids for pain management

Advances in Psychosomatic Medicine

Volumn 30, Issue , 2011, Pages 125-138

  Thaler, Adam ^a   Gupta, Anita ^a   Cohen, Steven P ^b,c,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CANNABINOID;

ARTICLE; CHRONIC DISEASE; HUMAN; NOCICEPTIVE RECEPTOR; PAIN; PERIPHERAL NEUROPATHY; SPASTICITY;

ANALGESICS, NON-NARCOTIC; CANNABINOIDS; CHRONIC DISEASE; HUMANS; MUSCLE SPASTICITY; NOCICEPTORS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84926117383     PISSN: 00653268     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000324070     Document Type: Article

References (56)

1. Geller T: Cannabinoids: a secret history. Chemical Heritage Newsmagazine 2007;25.
2. Grotenhermen F: Pharmacokinetics and pharmaco-dynamics of cannabinoids. Clin Pharmacokinet 2003;42:327-360.
3. Yamamoto T, Takada K: Role of cannabinoid receptor in the brain as it relates to drug reward. Jpn J Pharmacol 2000;84:229-236. (Pubitemid 32000447)
4. Galal A, Slade D, Gul W, El-Alfy AT, Ferreira D, Elsohly MA: Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications. Recent Pat CNS Drug Discov 2009;4: 112-136.
5. 9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005;168:657-690.
6. Wallace M, Schulteis G, Atkinson J, Wolfson T, Lazzaretto D, Bentley H, Gouaux B, Abramson I: Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007;107: 785-796. (Pubitemid 351325971)
7. Kraft B, Frickey N, Kaufmann R, Reif M, Frey R, Gustorff B, Kress HG: Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 2008;109:101-110.
8. Redmond W, Goffaux P, Potvin S, Marchand S: Analgesic and antihyperanalgesic effects of nabilone on experimental heat pain. Curr Med Res Opin 2008;24:1017-1024. (Pubitemid 351579158)
9. Holdcroft A, Maze M, Doré C, Tebbs S, Thompson S: A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006;104:1040-1046.
10. 9-tetrahdrocannabinol in postoperative pain. Pain 2003;106:169-172. (Pubitemid 37329627)
11. Beaulieu P: Effects of nabilone, a synthetic cannabi-noid, on postoperative pain. Can J Anaesth 2006;53: 769-775. (Pubitemid 44420062)
12. Selvi E, Lorenzini S, Garcia-Gonzalez E, Maggio R, Lazzerini PE, Capecchi PL, Balistreri E, Spreafico A, Niccolini S, Pompella G, Natale MR, Guideri F, Laghi Pasini F, Galeazzi M, Marcolongo R: Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin Exp Rheumatol 2008;26: 574-581.
13. Stebulis J, Johnson D, Rossetti R, Burstein SH, Zurier RB: Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eico-sanoids in human synovial cells. Life Sci 2008;83: 666-670.
14. Parker J, Atez F, Rossetti RG, Skulas A, Patel R, Zurier RB: Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid. Rheumatol Int 2008;28:631-635. (Pubitemid 351501661)
15. Blake D, Robson P, Ho M, Jubb RW, McCabe CS: Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006;45:50-52. (Pubitemid 43033874)
16. Nurmikko T, Serpell M, Hoggart B, Toomey PJ, Morlion BJ, Haines D: Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007;133:210-220. (Pubitemid 350141682)
17. Ellis R, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, Bentley H, Atkinson JH: Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009;34:672-680.
18. Abrams D, Jay C, Shade S, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL: Cannabis in painful HIV-associated sensory neuropathy. Neurology 2007;68:515-521.
19. Haney M, Rabkin J, Gunderson E, Foltin R: Dronabinol and marijuana in HIV+ marijuana smokers: acute effects on caloric intake and mood. Psychopharmacology 2005;181:170-178. (Pubitemid 41440928)
20. Finnerup N, Jensen O, Sindrup S: An evidence-based algorithm for the treatment of neuropathic pain. MedGenMed 2007;9:36.
21. Hosking R, Zajicek J: Therapeutic potential of canna-bis in pain medicine. Br J Anaesth 2008;101:59-68. (Pubitemid 351881914)
22. Pollmann W, Feneberg W: Current management of pain associated with multiple sclerosis. CNS Drugs 2008;22:291-324. (Pubitemid 351367440)
23. Rog D, Nurmikko T, Friede T, Young C: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65: 812-819. (Pubitemid 41362120)
24. Svendsen KB, Jensen TS, Bach FW: Does the can-nabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329:253.
25. Wade DT, Makela P, Robson P, House H, Bateman C: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-441. (Pubitemid 39117341)
26. Wade D, Robson P, House H, Makela P, Aram J: A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17: 21-29. (Pubitemid 36230977)
27. 9- Tetrahydrocannabinol shows antispastic and analgesic effects in a single-case double-blind trial. Eur Arch Psychiatry Clin Neurosci 1990;240:1-4. (Pubitemid 20323888)
28. Malfitano AM, Proto MC, Bifulco M: Cannabinoids in the management of spasticity associated with multiple sclerosis. Neuropsychiatr Dis Treat 2008;4: 847-853.
29. 9-tetrahydrocannabinol. J Clin Pharmacol 1981;21(8-9 suppl):413S-416S.
30. 9-Tetrahydrocannabinol in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987;7:39-50.
31. Collin C, Davies P, Mutiboko IK, Ratcliffe S, Sativex Spasticity in MS Study Group: Randomized controlled trial of cannabis-based medicine in spastic-ity caused by multiple sclerosis. Eur J Neurol 2007; 14:290-296. (Pubitemid 46384865)
32. Wade DT, Makela PM, House H, Bateman C, Robson P: Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12: 639-645. (Pubitemid 46940638)
33. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, UK MS Research Group: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicenter randomised placebo-controlled trial. Lancet 2003;362:1517-1526. (Pubitemid 37410189)
34. Killestein J, Hoogervorst EL, Reif M, Kalkers N F, van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH: Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002;58:1404-1407. (Pubitemid 34507170)
35. Wissel J, Haydn R, Müller J, Brenneis C, Berger T, Poewe W, Schelosky LD: Low-dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 2006; 253:1337-1341. (Pubitemid 44691559)
36. Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M: Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10:417-424. (Pubitemid 39117339)
37. 9- tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 2007;45:551-562. (Pubitemid 47206959)
38. 9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975;15: 139-143.
39. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S: A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008;9: 506-521.
40. Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D: Comparison of analgesic effects and patient tol-erability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 2008;336:199-201. (Pubitemid 351212676)
41. Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C: Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 2004;59: 440-452. (Pubitemid 38578684)
42. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U: Analgesic effect of the synthetic can-nabinoid CT-3 on chronic neuropathic pain. JAMA 2003;290:1757-1762. (Pubitemid 37430626)
43. Berman JS, Symonds C, Birch R: Efficacy of two cannabis-based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain 2004; 112:299-306. (Pubitemid 39550730)
44. Hall W, Solowij N: Adverse effects of cannabis. Lancet 1998;352:1611-1616. (Pubitemid 28515256)
45. Wang T, Collet J P, Shapiro S, Ware MA: Adverse effects of medical cannabinoids: a systematic review. CMAJ 2008;178:1669-1678. (Pubitemid 351899653)
46. Institute of Medicine: Marijuana and medicine: assessing the science base. Washington, National Academy Press, 1999.
47. Degenhardt L, Hall WD: The adverse effects of can-nabinoids: implications for use of medical marijuana. CMAJ 2008;178:1685-1686. (Pubitemid 351897984)
48. Cohen SP: Cannabinoids for chronic pain. BMJ 2008;336:167-168. (Pubitemid 351212650)
49. Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA: Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 2007; 167:221-228.
50. Fernandez-Espejo E, Viveros M, Nuñez L, Ellenbroek BA, Rodriguez de Fonseca F: Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl) 2009; 206:531-549.
51. Le Bec PY, Fatséas M, Denis C, Lavie E, Auriacombe M: Cannabis and psychosis: search of a casual link through a critical and systematic review (in French). Encephale 2009;35:377-385.
52. Lichtman AH, Martin BR: Cannabinoid tolerance and dependence. Handb Exp Pharmacol 2005;168: 691-717.
53. Kalant H: Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 2004;28: 849-863. (Pubitemid 39195275)
54. Hartman CA, Hopfer CJ, Haberstick B, Rhee SH, Crowley TJ, Corley R P, Hewitt JK, Ehringer MA: The association between cannabinoid receptor 1 gene (CNR1) and cannabis dependence symptoms in adolescents and young adults. Drug Alcohol Depend 2009;104:11-16.
55. Zuo L, Kranzler HR, Luo X: CNR1 variation modulates risk for drug and alcohol dependence. Biol Psychiatry 2007;62:616-626. (Pubitemid 47314382)
56. Zajicek J P, Sanders H P, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ: Cannabinoids in Multiple Sclerosis (CAMS) study: safety and efficacy data for 12 months follow-up. J Neurol Neurosurg Psychiatry 2005;76:1664-1669. (Pubitemid 41697631)